Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma

Ignyta, Inc.

, a precision oncology biotechnology company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for Ignyta's product candidate entrectinib for the treatment of neuroblastoma. "We are pleased that the EMA has provided this designation for entrectinib, adding to our orphan designations in the U.S. for the treatment of neuroblastoma and the treatment of TrkA-, TrkB-, TrkC-, ROS1- or ALK-positive non-small cell lung cancer and colorectal cancer," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "Entrectinib has the potential to address unmet needs of patients with rare cancers, and we will continue to aggressively pursue our clinical development program for entrectinib in solid tumors for the benefit of these patients."